The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.
A KAUST-led research team sequenced the first high-quality quinoa genome. This achievement may enhance our ability to feed the world's growing population. The research was conducted at King Abdullah University of Science and Technology. Why it matters: This breakthrough in genomics could lead to more resilient and nutritious crops, contributing to global food security efforts.
KAUST and KFSHRC have developed NanoRanger, a new gene sequencing system for identifying mutations causing genetic diseases. NanoRanger offers a faster and simpler process to detect DNA abnormalities at base resolution, building on existing long-read sequencing technologies. The system is designed to be cheaper and faster, targeting diseases prevalent in Saudi Arabia due to consanguinity. Why it matters: The technology has the potential to improve diagnosis and treatment of Mendelian diseases, which are especially prevalent in the Arab world.
A talk discusses the challenges of single-cell data analysis, such as feature sparsity and the effects of rare cells. AI/ML strategies are uniquely positioned to model this data. ImYoo, a startup founded in 2021, is applying single-cell model architectures for unsupervised discovery of patient groupings and predicting sample-level phenotypical data in autoimmune disease. Why it matters: This highlights the growing application of AI/ML in analyzing single-cell data for population-scale human health studies, an area ripe for innovation and improvement in the Middle East's growing biotech sector.
KAUST researchers analyzed the genome of strain RS24, a bacterium isolated from the Red Sea. The bacterium, named Candidatus Micropelagos thuwalensis RS24, belongs to the PS1 clade within Alphaproteobacteria. Genome sequencing revealed that RS24 and IMCC14465, while similar, are distinct species of the PS1 clade, containing genomic islands. Why it matters: This study advances understanding of microbial adaptation to extreme marine environments like the Red Sea, providing insights into the structure-function relationships within microbial communities.
KAUST researchers are analyzing the SARS-CoV-2 genome to identify potential targets for treatment and vaccine development. They are using the KAUST Metagenome Analysis Platform (KMAP) and the university's supercomputer to compare and analyze genomic data. The research focuses on identifying key genes for detection and treatment of COVID-19. Why it matters: This research contributes to the global effort to combat the pandemic and highlights KAUST's capabilities in genomic data analysis and computational bioscience.
KAUST and Oxford Nanopore Technologies have signed an MoU to collaborate on multi-omics research, building on previous work such as the NanoRanger technique developed by KAUST's Mo Li. KAUST will gain early access to Oxford Nanopore’s sequencing technology, while Oxford Nanopore will access KAUST's Core Labs. Why it matters: This partnership enhances KAUST's research capabilities in areas like rare diseases and desert agriculture, and provides Oxford Nanopore with a launchpad to engage with Saudi Arabia's research community.
The article discusses the rise of large language models like ChatGPT and Gemini. It highlights their role in driving the first wave of AI development. Why it matters: While lacking specifics, the article suggests ongoing interest in the impact and future of LLMs, a key area of AI research and development.